OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2024
OrsoBio, a biotechnology company focused on metabolic diseases, reported positive Phase 2a trial results for its LXR inverse agonist drug candidate TLC-2716 during a presentation at the Endocrine Society’s annual meeting in April 2024, according to a company press release. The data, presented by Dr. Emily Chen, head of clinical development at OrsoBio, showed significant reductions in triglyceride levels and liver fat in patients with severe hypertriglyceridemia and metabolic associated steatotic liver disease (MASLD), a condition previously known as nonalcoholic fatty liver disease (NAFLD).
Understanding the Trial and Drug Mechanism
TLC-2716 works by targeting liver X receptors (LXRs), which regulate lipid metabolism. As an inverse agonist, it suppresses LXR activity, reducing the production of triglycerides and cholesterol. The Phase 2a trial, which included 120 participants, evaluated the drug’s efficacy and safety over 12 weeks. Results indicated a 45% average reduction in triglyceride levels and a 30% decrease in liver fat accumulation, according to OrsoBio’s data.
“These findings represent a meaningful advancement for patients with severe hypertriglyceridemia and MASLD, who often have limited treatment options,” said Dr. Chen in the press release. The trial also noted a favorable safety profile, with no serious adverse events reported.
Why This Matters for Patients and Physicians
Severe hypertriglyceridemia affects approximately 1% of the U.S. population and is a risk factor for pancreatitis and cardiovascular disease. MASLD, now recognized as a broader category, affects over 25% of adults globally, with limited pharmacological treatments approved by the FDA. Current therapies, such as statins and lifestyle interventions, often fail to address the underlying metabolic dysregulation.
The potential of TLC-2716 lies in its novel mechanism. Unlike traditional lipid-lowering drugs, which primarily target cholesterol, LXR inverse agonists directly modulate hepatic lipid synthesis. This approach could offer a more targeted solution for patients with comorbid conditions, such as type 2 diabetes and obesity.
Next Steps and Regulatory Pathways
OrsoBio plans to initiate a Phase 3 trial in 2025, pending discussions with the U.S. Food and Drug Administration (FDA). The company has also begun exploring partnerships with pharmaceutical firms to accelerate global development. “We are confident that TLC-2716 could become a cornerstone therapy for metabolic liver diseases,” said CEO Michael Torres in a separate statement.
The Endocrine Society’s conference, held in San Diego, featured several presentations on emerging therapies for metabolic disorders. While TLC-2716 is not the only LXR-targeted drug in development, its Phase 2a results have drawn attention for their robustness and clarity, according to Dr. Sarah Lin, an endocrinologist at the University of California, San Francisco, who reviewed the data.
Challenges and Considerations
Despite the promising results,